SELLAS Life Sciences Reports First Quarter 2024 Financial Results …

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical …

CouponFollow Extension

$7
OFF

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

3 days ago · Net Loss: The net loss was $7.1 million for the third quarter of 2024, or a basic and diluted loss per share of $0.10, as compared to a net loss of $9.3 million for the third quarter of …

businessinsider.com

$5
OFF

SELLAS Life Sciences Reports First Quarter 2024 Financial Results …

1 week from now

May 14, 2024 · The financial results for the first quarter of 2024 indicate some positive trends for SELLAS Life Sciences. The company's R&D expenses decreased to $5.1 million from $7.2 …

stocktitan.net

$5
OFF

SELLAS Life Sciences Reports First Quarter 2024 Financial

1 week from now

May 14, 2024 · Financial Results for the First Quarter 2024: R&D Expenses: Research and development expenses for the quarter ended March 31, 2024 were $5.1 million, compared to …

globenewswire.com

$4
OFF

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

3 days ago · Financial Results for the Third Quarter 2024: R&D Expenses : Research and development expenses for the quarter ended September 30, 2024, were $4.4 million, …

einnews.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results - Nasdaq

1 week from now

Sep 30, 2024 · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024 , the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

nasdaq.com

FAQs about SELLAS Life Sciences Reports First Quarter 2024 Financial Results … Coupon?

What were the financial results for the third quarter 2024?

Financial Results for the Third Quarter 2024: R&D Expenses: Research and development expenses for the quarter ended September 30, 2024, were $4.4 million, compared to $5.8 million for the same period in 2023. ...

Where can I find more information about Sellas & gfh009?

The Company is also developing SLS009 (formerly GFH009), a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China. For more information on SELLAS, please visit www.sellaslifesciences.com. ...

What was the net loss in the third quarter of 2024?

Net Loss: The net loss was $7.1 million for the third quarter of 2024, or a basic and diluted loss per share of $0.10, as compared to a net loss of $9.3 million for the third quarter of 2023, or a basic and diluted loss per share of $0.33. ...